Quarterly report pursuant to Section 13 or 15(d)

Liquidity (Details Narrative)

v3.8.0.1
Liquidity (Details Narrative) - USD ($)
3 Months Ended
Jan. 26, 2018
Jan. 05, 2018
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Accumulated deficit     $ 77,393,486   $ 65,698,101
Proceeds from sale of stock     11,856,655 $ 41,349,957  
Amount received upon achievement     $ 6,250,000    
Number of warrants issued to purchase shares of common stock     2,288,500    
Warrants exercise price per share     $ 6.33    
Cash and cash equivalents     $ 70,955,652   $ 62,537,495
2018 CFF Award [Member]          
Amount received for development award $ 25,000,000        
Sales Agreement [Member]          
Proceeds from sale of stock       $ 13,268,208  
Investment Agreement [Member] | Phase 2b Clinical Trial [Member]          
Amount received for development award     6,250,000    
Investment Agreement [Member] | Phase 2b Clinical Trial [Member] | May 2018 [Member]          
Amount received upon achievement     $ 6,250,000    
Cantor Fitzgerald & Co. [Member] | Sales Agreement [Member]          
Number of common stock value sold   $ 50,000,000      
Number of common stock share sold   1,500,000      
Proceeds from sale of stock   $ 11,200,000      
Cystic Fibrosis Foundation warrants [Member]          
Number of warrants issued to purchase shares of common stock 1,000,000   1,000,000    
Warrants exercise price per share $ 13.20   $ 13.20    
Number of warrants exercisable 500,000   500,000    
Cystic Fibrosis Foundation warrants [Member] | Investment Agreement [Member]          
Number of warrants exercisable 500,000   500,000